Mayne Pharma has acquired on-market dermatology portfolio Foam Assets from GSK for $50.1m.
The Foam Assets includes US rights to Fabior and Sorilux, Canadian rights to Luxiq and Olux-E and Mexican rights to betamethasone foam.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As per the deal, Mayne Pharma will secure the approved regulatory filings, trademarks, marketing materials, select product inventory, related medical and technical data and obtain licenses for related patents.
Fabior (tazarotene) Foam, 0.1% is a topical product for the treatment of acne, which affects up to 50 million Americans every year.
Sorilux (calcipotriene) Foam, 0.005% is a topical product meant for mild-to-moderate plaque psoriasis, impacting up to 6 million Americans every year.
Mayne Pharma’s specialist brands division and existing sales team will market Fabior and Sorilux.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBoth products will be relaunched next fiscal year and until then, GSK will continue to distribute Fabior and Sorilux as per a transition services arrangement.
GSK will continue to distribute the non-US dermatology assets in the short term.
Mayne Pharma plans to out-license these products to new partners.
